Biotech & Genetics · Projected milestone
RNA-editing medicine demonstrates clinical benefit
70% by 2038 · including earlier years
The year is an editorial timing estimate. The percentage applies to occurrence by the stated deadline. These estimates are not calibrated odds.
A controlled human trial shows a prespecified clinically meaningful benefit from editing a target RNA sequence without intended genomic-DNA alteration, beyond reporting editing or protein biomarkers alone.
Explore this milestone on the interactive mapWhat the forecast means
Milestone stage: clinical validation
sponsor-reported in-patient RNA editing and protein correction
Timing window: 2027–2037. An editorial range, not a statistical confidence interval.
Completion criteria: A controlled human trial shows a prespecified clinically meaningful benefit from editing a target RNA sequence without intended genomic-DNA alteration, beyond reporting editing or protein biomarkers alone. Resolve only from inspectable evidence meeting every stated criterion; a plan or extrapolation does not resolve it.
This page describes a forecast, rather than an achieved result. Read the methodology and assumptions.
Built on
Led to
Sources & evidence
- Wave RestorAATion-2 RNA editing update, 18 May 2026 2026-05-18
Investigational RNA editing clinical data in AATD; sponsor report is not regulatory approval or independent confirmation.
Astra editorial synthesis; cited researchers retain credit for their results
Record reviewed 2026-10-18